PSP Research’s Inhibrx INBX Stock Holding History

PSP Research’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,927	Closed	-$466K	–	82
2026 Q1	$466K	Buy	6,927 +538	+8%	+$39.9K	0.33%	28
2025 Q4	$505K	Buy	+6,389	New	+$435K	0.44%	74

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PSP Research's INBX Position: Q2 2026 in Review

PSP Research sold out of Inhibrx (INBX) in Q2 2026, closing a stake of 6,927 shares — an estimated $466K sold.

PSP Research first reported a position in INBX in Q4 2025 and held it in 2 quarters. The position peaked at $505K in Q4 2025. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

PSP Research reported no remaining Inhibrx position as of Q2 2026 after selling out during the quarter.
PSP Research sold 6,927 Inhibrx shares in Q2 2026, an estimated $466K.
PSP Research first reported a position in Inhibrx in Q4 2025 and held it in 2 quarters.
PSP Research's Inhibrx position peaked at $505K in Q4 2025.
163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.